RecruitingPhase 4NCT06834165

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

Sponsor

ARS Pharmaceuticals, Inc.

Enrollment

600 participants

Start Date

May 20, 2025

Study Type

INTERVENTIONAL

Conditions

Allergic Reactions

Summary

The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.

Eligibility

Min Age: 4 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adrenaline and a drug called Neffy for people with allergic reactions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 4 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeffy

Epinephrine nasal spray

DRUGAdrenaline

Epinephrine injection

Locations(6)

Orso Health, Inc.

La Jolla, California, United States

Children's National Hospital

Washington D.C., District of Columbia, United States

Endeavor Health

Glenview, Illinois, United States

University Of Michigan

Ann Arbor, Michigan, United States

Weill Cornell Medicine/NewYork Presbyterian Hospital

New York, New York, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06834165